Clinical Trial Goal
To find out:
- The highest dose of PIT565 that's safe to give
- If PIT565 is safe and works well to treat B-ALL or B-NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following that has relapsed or is refractory:
- B-ALL
- B-NHL. Some examples include:
- Burkitt lymphoma
- Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Primary Mediastinal large B-cell lymphoma (PMBCL)
- Waldenström macroglobulinemia
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
PIT565 is a tri-specific antibody that targets CD19, CD3 and CD2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- PIT565 – Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to about 2 years.
The Food and Drug Administration (FDA) has not yet approved PIT565.
Contacts
Novartis Pharmaceuticals, 1-888-669-6682, novartis.email@novartis.com
Novartis Pharmaceuticals, +41613241111, novartis.email@novartis.com
Locations
Sponsors
lead: Novartis Pharmaceuticals
